Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Medical Education

Date Submitted: Jan 26, 2025
Date Accepted: Aug 21, 2025

The final, peer-reviewed published version of this preprint can be found here:

Assessing Pharmacists’ Use and Perception of AI Chatbots in Pharmacy Practice: Cross-Sectional Survey Study

Li A, Sheehan AH, Giuliano C, Dobry P, Walker P, Philips J, Jordan J

Assessing Pharmacists’ Use and Perception of AI Chatbots in Pharmacy Practice: Cross-Sectional Survey Study

JMIR Med Educ 2025;11:e71767

DOI: 10.2196/71767

PMID: 41271206

PMCID: 12680932

Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

Assessing Pharmacists’ Use and Perception of Artificial Intelligence Chatbots in Pharmacy Practice: Survey and Instrument Validation Study

  • Anly Li; 
  • Amy Heck Sheehan; 
  • Christopher Giuliano; 
  • Paul Dobry; 
  • Paul Walker; 
  • Jennifer Philips; 
  • Joseph Jordan

ABSTRACT

Background:

Use of artificial intelligence (AI) based large language model chatbots, such as ChatGPT, have become increasingly popular in many disciplines. However, concerns exist regarding ethics, legal considerations, accuracy, and reproducibility with its use in healthcare practice, education, and research.

Objective:

This study aims to assess current perceptions and use of artificial intelligence (AI) chatbots in pharmacy practice from the perspective of a pharmacist preceptor and to determine factors that may influence the use of AI chatbots in practice.

Methods:

A cross-sectional survey of pharmacy practice preceptors from Indiana, Illinois, and Michigan was conducted using the validated Technology Acceptance Model Edited to Assess ChatGPT Adoption (TAME-ChatGPT) survey tool to collect information regarding current use of AI chatbots and factors associated with use including ease of use, perceived risk, technology or social influences, anxiety, and perceived usefulness.

Results:

A total of 194 responses (10.3% response rate) were received. Approximately one third (n=59, 30.5%) of respondents reported having used an AI chatbot, with 51.6% (n=100) indicating that they plan to start or will continue using chatbots in the future. In practice, common uses for AI chatbots included summarizing information, letter of recommendation writing, and obtaining disease state information. The two main constructs associated with use of chatbots identified from the TAME-ChatGPT tool included perceived risk of using AI and attitude towards AI. Factors that predicted pharmacists' current use of AI chatbots included positive attitude towards technology, coworker use of AI, and working in academia.

Conclusions:

The majority of pharmacist respondents had not used an AI chatbot and were unlikely to make patient care decisions based on information from a chatbot. The TAME-ChatGPT survey is validated for assessing chatbot use and attitudes among pharmacists, and future studies using this survey tool can guide the implementation of chatbots into pharmacy practice.


 Citation

Please cite as:

Li A, Sheehan AH, Giuliano C, Dobry P, Walker P, Philips J, Jordan J

Assessing Pharmacists’ Use and Perception of AI Chatbots in Pharmacy Practice: Cross-Sectional Survey Study

JMIR Med Educ 2025;11:e71767

DOI: 10.2196/71767

PMID: 41271206

PMCID: 12680932

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.